We want to share a press release from Forge Biologics with promising news for those affected by Krabbe Disease:
“Five patients treated with FBX-101 show positive safety and efficacy results, including significant improvements in motor function”
“Designation provides opportunities for further global acceptance of Forge’s manufacturing process and facility through additional reviews and inspections”
To read the full press release: https://www.forgebiologics.com/forge-biologics-novel-aav-gene-therapy-fbx-101-for-patients-with-krabbe-disease-is-granted-uks-innovation-passport-designation/